If you look at the chart of consolidated sales in the presentation slides, note that measured over 4 halves, sales growth is rather modest for a so-called growth stock.
The half year announcement is silent on a key metric - the number of tests sold. Why?
On the assumption that the $A stays high, my 2011 intrinsic value on this stock has fallen below $2.00. Sell?
Add to My Watchlist
What is My Watchlist?
